AN2 Therapeutics is a clinical-stage biotech company advancing novel small molecule therapeutics derived from its boron chemistry platform to address serious and underserved infectious diseases and other high-need areas. The company’s pipeline includes epetraborole, a once-daily oral candidate for non-tuberculous mycobacterial (NTM) lung disease with orphan designation, as well as programs in Chagas disease, melioidosis, and early-stage oncology and infectious targets. AN2’s approach leverages differentiated boron-based chemistry to create potential best-in-class treatments for conditions with limited current options, reflecting a commitment to high-impact medicines for patients with critical unmet needs.